Price sensitivity among formulation companies is declining amid a
receding threat of supply chain disruptions from Chinese suppliers,
which had also occurred in the past, he said. Considering that India
has the highest number of API facilities approved by the US Food and
Drug Administration, it will remain a critical part of the global
supply channel, Munde noted.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/indian-api-makers-benefit-as-global-buyers-ditch-china/articleshow/77228150.cms
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment